🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU

MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal

• Aurelie Najm on Twitter: "RABBIT registry and MACE in RA
No difference…

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN

• EnvisionRheumat on Twitter: "#EULAR2022 
How to Manage (HOT): Lupus Ne…

Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE

Visual symptoms in GCA: should we take it on face value? @cmukhtyar group tertiary rheum/ophthal n=350 consecutive GCA pts diagnosed (bx/PET) visual symptoms 29% ocular signs 13% Not all symptoms = signs No doubt not all symptoms of same concern POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN

@Yuz6Yusof on breakthrough infections & severe #COVID in RTX treatment #EULAR2022 🦠Rate of mod/severe COVID infection comparable to pre-pandemic severe infection rate 💉High vaccination rate prevented severe disease 📊Consider #comorbidities & low IgG in risk-benefit assessment https://t.co/PGUVbHD7i2

BE COMPLETE RCT Bimekizumab vs. PBO in TNFiIR PsA pts meets its primary criteria at 16wks w/ -ACR50 43% -PASI 90 69% and MDA achieved in 40+% pts No new safety signal. @RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc

Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6

RA & dementia - it's getting more damning RA dementia risk: HR 1.25 from Korean nationwide data: RA n=138,592 this follows @MyasoedovaElena's data RA systemic inflamm leading to dementia (AD, vascular)? Need to understand if any DMARD protective OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj

Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst

#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou ⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts ⭐️UIP seen in 88% of deceased patients, 56% of living ⭐️Median survival 5.3 years @RheumNow https://t.co/tGBQ5GBlVg

Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q

Mestre-Torres et al. Features at GCA diagnosis that predict permanent vision loss. Age>75, jaw claudication, amaurosis fugax increase risk. Systemic symptoms decrease risk @RheumNow #EULAR2022 POS0271 https://t.co/FPC9R1v8S3

FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04) ⚡️Detects metabolic activity and tissular inflammation ⚡️Correlates with MRI changes in PsA ⚡️Is associated w/ progression of joint damage ⚡️Is sensitive to change An exciting new imaging modality! @RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC